From Casetext: Smarter Legal Research

In re Generic Pharm. Pricing Antitrust Litig.

United States District Court, E.D. Pennsylvania
May 25, 2022
MDL 2724 (E.D. Pa. May. 25, 2022)

Opinion

MDL 2724 16-MD-2724

05-25-2022

IN RE GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION v. Actavis Holdco U.S., Inc. THIS DOCUMENT RELATES TO Reliable Pharmacy Individual Action No. 19-6044


CYNTHIA M. RUFE, J.

ORDER

CYNTHIA M. RUFE, J.

AND NOW, this 25th day of May 2022, upon consideration of Distributor Defendants' Motion to Dismiss [Doc. No. 72 in Civil Action No. 19-6044], and the responses and replies thereto, and for the reasons stated in the accompanying Memorandum Opinion, it is hereby ORDERED that the Motion is GRANTED. The claims asserted against AmerisourceBergen Drug Corp. (“ABDC”), H.D. Smith, LLC, Cardinal Health, Inc., The Harvard Drug Group, LLC, McKesson Corp., Morris & Dickson Co., LLC, Red Oak Sourcing, LLC, Walgreens Boots Alliance, Inc., and Walgreens Boots Alliance Development GmbH (“WBAD”) are DISMISSED without prejudice. Plaintiffs are granted leave to file an amended complaint no later than June 24, 2022.

It is so ORDERED.

Summaries of

In re Generic Pharm. Pricing Antitrust Litig.

United States District Court, E.D. Pennsylvania
May 25, 2022
MDL 2724 (E.D. Pa. May. 25, 2022)
Case details for

In re Generic Pharm. Pricing Antitrust Litig.

Case Details

Full title:IN RE GENERIC PHARMACEUTICALS PRICING ANTITRUST LITIGATION v. Actavis…

Court:United States District Court, E.D. Pennsylvania

Date published: May 25, 2022

Citations

MDL 2724 (E.D. Pa. May. 25, 2022)